Wegovy and Blood Clots Overview Wegovy lawsuits claim that Novo Nordisk, the manufacturer of the weight loss drug, failed to warn users about blood clot-related injuries, such as deep vein thrombosis (DVT) and pulmonary embolism
There is no characterised dose-response curve for adverse effects
These inhibitors bind to the enzymes active site, effectively blocking its activity
Swallowable intragastric balloon program and GLP1 agonist combined treatment for obesity: an international multicenter study
GLP-1 stimulates insulin secretion, inhibits glucagon secretion, slows gastric emptying, and promotes satiety, all of which contribute to weight loss
Another poster focuses on age-friendly care, examining ways organizations can better support older adults through structured care practices that address key patient needs